RxDoctor Payments Data

Joel Saldana, MD

Family Medicine · Kenedy, TXNPI 1427021997

Payments from drug & device makers

$229in general payments, 2019–2025

Across 6 payments — averaging $38.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$134
  • Neurocrine Biosciences, Inc.$28
  • Ascendis Pharma Endocrinology Inc$23
  • Lilly USA, LLC$16
  • Abbott$14
  • Amarin Pharma, Inc.$13

What the payments were for

  • Food & beverage$229100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$229 in reported general payments places this provider in the 35th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$151,375
Medicare patients
315
Services billed
2,130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide122$148,134
JardianceEmpagliflozin64$76,135
EliquisApixaban95$69,527
JanuviaSitagliptin Phosphate94$64,865
TrulicityDulaglutide49$49,133
OzempicSemaglutide32$33,008
FarxigaDapagliflozin Propanediol40$26,385
XareltoRivaroxaban32$23,343
MyrbetriqMirabegron21$15,879
Soliqua 100-33Insulin Glargine/Lixisenatide12$10,753
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$9,140
VascepaIcosapent Ethyl22$8,229
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$7,625
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,213
BrilintaTicagrelor13$6,555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$16$197,267171 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Kenedy

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →